Ameriprise Financial Inc. cut its stake in LivaNova PLC (NASDAQ:LIVN) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 144,350 shares of the company’s stock after selling 1,900 shares during the quarter. Ameriprise Financial Inc. owned about 0.30% of LivaNova worth $10,113,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in LIVN. PNC Financial Services Group Inc. increased its holdings in shares of LivaNova by 9.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock valued at $105,000 after acquiring an additional 153 shares during the period. Riverhead Capital Management LLC increased its holdings in shares of LivaNova by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after acquiring an additional 763 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of LivaNova in the 2nd quarter valued at $204,000. Bessemer Group Inc. purchased a new position in shares of LivaNova in the 2nd quarter valued at $220,000. Finally, Martingale Asset Management L P purchased a new position in shares of LivaNova in the 2nd quarter valued at $221,000. Institutional investors and hedge funds own 86.00% of the company’s stock.
In other LivaNova news, Director Hugh M. Morrison sold 1,830 shares of LivaNova stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total transaction of $161,040.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alfred J. Novak sold 2,000 shares of LivaNova stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Insiders sold a total of 6,830 shares of company stock valued at $569,350 in the last three months. Insiders own 0.28% of the company’s stock.
LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.17. The firm had revenue of $309.70 million during the quarter, compared to analysts’ expectations of $301.22 million. LivaNova had a return on equity of 9.33% and a net margin of 4.63%. The business’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 EPS. research analysts expect that LivaNova PLC will post 3.33 earnings per share for the current fiscal year.
A number of research analysts have recently issued reports on the company. ValuEngine downgraded LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research raised LivaNova from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a research report on Thursday, November 9th. BTIG Research reissued a “hold” rating on shares of LivaNova in a research report on Tuesday, November 7th. Piper Jaffray Companies reissued a “buy” rating and issued a $85.00 price objective on shares of LivaNova in a research report on Friday, November 3rd. Finally, Canaccord Genuity reissued a “hold” rating and issued a $71.00 price objective on shares of LivaNova in a research report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $79.71.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.